PUBLISHER: Allied Market Research | PRODUCT CODE: 1566980
PUBLISHER: Allied Market Research | PRODUCT CODE: 1566980
Vinca Alkaloid Compounds Market By Product Type (Vinblastine, Vincristine, Vindesine) , By End User (Hospitals, Clinics, Academic & Research Institutes) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Vinca Alkaloid Compounds Market
The vinca alkaloid compounds market was valued at $81.0 million in 2023 and is projected to reach $161.5 million by 2033, growing at a CAGR of 7.2% from 2024 to 2033.
Vinca alkaloid is a naturally occurring secondary metabolite, majorly extracted from the periwinkle plant Catharanthus roseus. The compound is utilized for its anti-mitotic and anti-microtubule properties. During cell division, vinca alkaloid compounds block the polymerization of beta-tubulin, a protein necessary to provide structural support during cell division. This blockage results in cytotoxicity and cell death. This property of the compounds is utilized as a therapeutic approach for the treatment of various cancers, including lymphomas, leukemias, breast cancer, and lung cancer.
Increase in the prevalence of various cancer forms and advancements in the development of therapeutic drugs are the significant drivers of the vinca alkaloid compounds market. Furthermore, constant R&D efforts toward the generation of medications and treatment solutions for the mitigation of cancer boost the demand for vinca alkaloid compounds. The synthesis of this secondary metabolite using endophytes is projected to be a significant trend in the future. Extraction of vinca alkaloid compounds directly from the plant is highly inefficient and intricate. Contrarily, the process of microbial fermentation of endophytes is a notably feasible and competent procedure, which is anticipated to facilitate and boost the production of anti-cancer drugs in upcoming years.
However, the potential side-effects of vinca alkaloid compounds are severe, including neurotoxicity and myelosuppression. This limits the usage of compounds to a certain extent, hence restraining the development of the market. Moreover, the tumor cells develop a resistance to the drugs derived from vinca alkaloid compounds over long durations, lowering their long-term efficacy and hampering the market growth. On the contrary, innovations in drug development have led to the harnessing of anti-cancerous properties of vinca alkaloid compounds by eliminating their limitations, presenting lucrative opportunities for the expansion of the market. For instance, according to a research paper published on the National Library of Medicine, the side-effects of vinca alkaloid compounds are mitigated using combination therapy, in which the compound is combined with some other chemotherapy drug, enhancing the anti-tumor effect of the cocktail drug.
Segment Review
The vinca alkaloid compounds market is segmented into product type, end user, and region. On the basis of product type, the market is divided into vinblastine, vincristine, and vindesine. As per end user, it is classified into hospitals, clinics, and academic & research institutes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of product type, the vincristine segment dominated the market in 2023.
As per end user, the hospitals segment accounted for a high market share in 2023.
Region wise, North America was the highest revenue generator in 2023.
Competition Analysis
The leading players operating in the global vinca alkaloid compounds market include Accord Healthcare Limited, Eli Lilly and Company., Fresenius Kabi AG, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Medline Industries, LP., Pfizer Inc., Pierre Fabre S.A, Talon Pharmaceuticals, Teva Pharmaceutical Industries Limited, and Viatris Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Product Type
- Vinblastine
- Vincristine
- Vindesine
By End User
- Hospitals
- Clinics
- Academic Research Institutes
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players:
- Accord Healthcare Limited
- Eli Lilly and Company.
- Fresenius Kabi AG
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- Medline Industries, LP.
- Pfizer Inc.
- Pierre Fabre S.A
- Talon Pharmaceuticals
- Teva Pharmaceutical Industries Limited
- Viatris Inc.
TABLE OF CONTENTS
CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
CHAPTER 4: VINCA ALKALOID COMPOUNDS MARKET, BY PRODUCT TYPE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Product Type
- 4.2. Vinblastine
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Vincristine
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Vindesine
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
CHAPTER 5: VINCA ALKALOID COMPOUNDS MARKET, BY END USER
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By End User
- 5.2. Hospitals
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Clinics
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- 5.4. Academic Research Institutes
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
CHAPTER 6: VINCA ALKALOID COMPOUNDS MARKET, BY REGION
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Region
- 6.2. North America
- 6.2.1. Key Market Trends and Opportunities
- 6.2.2. Market Size and Forecast, By Product Type
- 6.2.3. Market Size and Forecast, By End User
- 6.2.4. Market Size and Forecast, By Country
- 6.2.5. U.S. Vinca Alkaloid Compounds Market
- 6.2.5.1. Market Size and Forecast, By Product Type
- 6.2.5.2. Market Size and Forecast, By End User
- 6.2.6. Canada Vinca Alkaloid Compounds Market
- 6.2.6.1. Market Size and Forecast, By Product Type
- 6.2.6.2. Market Size and Forecast, By End User
- 6.2.7. Mexico Vinca Alkaloid Compounds Market
- 6.2.7.1. Market Size and Forecast, By Product Type
- 6.2.7.2. Market Size and Forecast, By End User
- 6.3. Europe
- 6.3.1. Key Market Trends and Opportunities
- 6.3.2. Market Size and Forecast, By Product Type
- 6.3.3. Market Size and Forecast, By End User
- 6.3.4. Market Size and Forecast, By Country
- 6.3.5. Germany Vinca Alkaloid Compounds Market
- 6.3.5.1. Market Size and Forecast, By Product Type
- 6.3.5.2. Market Size and Forecast, By End User
- 6.3.6. France Vinca Alkaloid Compounds Market
- 6.3.6.1. Market Size and Forecast, By Product Type
- 6.3.6.2. Market Size and Forecast, By End User
- 6.3.7. UK Vinca Alkaloid Compounds Market
- 6.3.7.1. Market Size and Forecast, By Product Type
- 6.3.7.2. Market Size and Forecast, By End User
- 6.3.8. Italy Vinca Alkaloid Compounds Market
- 6.3.8.1. Market Size and Forecast, By Product Type
- 6.3.8.2. Market Size and Forecast, By End User
- 6.3.9. Spain Vinca Alkaloid Compounds Market
- 6.3.9.1. Market Size and Forecast, By Product Type
- 6.3.9.2. Market Size and Forecast, By End User
- 6.3.10. Rest of Europe Vinca Alkaloid Compounds Market
- 6.3.10.1. Market Size and Forecast, By Product Type
- 6.3.10.2. Market Size and Forecast, By End User
- 6.4. Asia-Pacific
- 6.4.1. Key Market Trends and Opportunities
- 6.4.2. Market Size and Forecast, By Product Type
- 6.4.3. Market Size and Forecast, By End User
- 6.4.4. Market Size and Forecast, By Country
- 6.4.5. Japan Vinca Alkaloid Compounds Market
- 6.4.5.1. Market Size and Forecast, By Product Type
- 6.4.5.2. Market Size and Forecast, By End User
- 6.4.6. China Vinca Alkaloid Compounds Market
- 6.4.6.1. Market Size and Forecast, By Product Type
- 6.4.6.2. Market Size and Forecast, By End User
- 6.4.7. Australia Vinca Alkaloid Compounds Market
- 6.4.7.1. Market Size and Forecast, By Product Type
- 6.4.7.2. Market Size and Forecast, By End User
- 6.4.8. India Vinca Alkaloid Compounds Market
- 6.4.8.1. Market Size and Forecast, By Product Type
- 6.4.8.2. Market Size and Forecast, By End User
- 6.4.9. South Korea Vinca Alkaloid Compounds Market
- 6.4.9.1. Market Size and Forecast, By Product Type
- 6.4.9.2. Market Size and Forecast, By End User
- 6.4.10. Rest of Asia-Pacific Vinca Alkaloid Compounds Market
- 6.4.10.1. Market Size and Forecast, By Product Type
- 6.4.10.2. Market Size and Forecast, By End User
- 6.5. LAMEA
- 6.5.1. Key Market Trends and Opportunities
- 6.5.2. Market Size and Forecast, By Product Type
- 6.5.3. Market Size and Forecast, By End User
- 6.5.4. Market Size and Forecast, By Country
- 6.5.5. Brazil Vinca Alkaloid Compounds Market
- 6.5.5.1. Market Size and Forecast, By Product Type
- 6.5.5.2. Market Size and Forecast, By End User
- 6.5.6. Saudi Arabia Vinca Alkaloid Compounds Market
- 6.5.6.1. Market Size and Forecast, By Product Type
- 6.5.6.2. Market Size and Forecast, By End User
- 6.5.7. South Africa Vinca Alkaloid Compounds Market
- 6.5.7.1. Market Size and Forecast, By Product Type
- 6.5.7.2. Market Size and Forecast, By End User
- 6.5.8. Rest of LAMEA Vinca Alkaloid Compounds Market
- 6.5.8.1. Market Size and Forecast, By Product Type
- 6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
- 7.1. Introduction
- 7.2. Top Winning Strategies
- 7.3. Product Mapping of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
- 8.1. Accord Healthcare Limited
- 8.1.1. Company Overview
- 8.1.2. Key Executives
- 8.1.3. Company Snapshot
- 8.1.4. Operating Business Segments
- 8.1.5. Product Portfolio
- 8.1.6. Business Performance
- 8.1.7. Key Strategic Moves and Developments
- 8.2. Eli Lilly And Company.
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Operating Business Segments
- 8.2.5. Product Portfolio
- 8.2.6. Business Performance
- 8.2.7. Key Strategic Moves and Developments
- 8.3. Fresenius Kabi AG
- 8.3.1. Company Overview
- 8.3.2. Key Executives
- 8.3.3. Company Snapshot
- 8.3.4. Operating Business Segments
- 8.3.5. Product Portfolio
- 8.3.6. Business Performance
- 8.3.7. Key Strategic Moves and Developments
- 8.4. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- 8.4.1. Company Overview
- 8.4.2. Key Executives
- 8.4.3. Company Snapshot
- 8.4.4. Operating Business Segments
- 8.4.5. Product Portfolio
- 8.4.6. Business Performance
- 8.4.7. Key Strategic Moves and Developments
- 8.5. Medline Industries, LP.
- 8.5.1. Company Overview
- 8.5.2. Key Executives
- 8.5.3. Company Snapshot
- 8.5.4. Operating Business Segments
- 8.5.5. Product Portfolio
- 8.5.6. Business Performance
- 8.5.7. Key Strategic Moves and Developments
- 8.6. Pfizer Inc.
- 8.6.1. Company Overview
- 8.6.2. Key Executives
- 8.6.3. Company Snapshot
- 8.6.4. Operating Business Segments
- 8.6.5. Product Portfolio
- 8.6.6. Business Performance
- 8.6.7. Key Strategic Moves and Developments
- 8.7. Pierre Fabre S.A
- 8.7.1. Company Overview
- 8.7.2. Key Executives
- 8.7.3. Company Snapshot
- 8.7.4. Operating Business Segments
- 8.7.5. Product Portfolio
- 8.7.6. Business Performance
- 8.7.7. Key Strategic Moves and Developments
- 8.8. Talon Pharmaceuticals
- 8.8.1. Company Overview
- 8.8.2. Key Executives
- 8.8.3. Company Snapshot
- 8.8.4. Operating Business Segments
- 8.8.5. Product Portfolio
- 8.8.6. Business Performance
- 8.8.7. Key Strategic Moves and Developments
- 8.9. Teva Pharmaceutical Industries Limited
- 8.9.1. Company Overview
- 8.9.2. Key Executives
- 8.9.3. Company Snapshot
- 8.9.4. Operating Business Segments
- 8.9.5. Product Portfolio
- 8.9.6. Business Performance
- 8.9.7. Key Strategic Moves and Developments
- 8.10. Viatris Inc.
- 8.10.1. Company Overview
- 8.10.2. Key Executives
- 8.10.3. Company Snapshot
- 8.10.4. Operating Business Segments
- 8.10.5. Product Portfolio
- 8.10.6. Business Performance
- 8.10.7. Key Strategic Moves and Developments
